SNPMiner Trials (Home Page)
Report for SNP rs3781727
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 A Clinical Trail to Investigate the Influence of SLCO2B1 Polymorphism on the Pharmacokinetic Characteristics of Voriconazole in CYP2C19 Poor Metabolizers
A clinical trail to investigate the influence of SLCO2B1 polymorphism on the pharmacokinetic characteristics of voriconazole in CYP2C19 poor metabolizers
NCT02906176 Healthy Volunteers Drug: Vfend (voriconazole) intravenous infusion Drug: Vfend (voriconazole) tablet
Inclusion Criteria: - Healthy male volunteer who is a CYP2C19 Poor metabolizer with rs3781727 SNP wild or variant genotype Exclusion Criteria: - History of clinically significant respiratory, cardiovascular, renal, hepatic, hematologic, neurological disorder Inclusion Criteria: - Healthy male volunteer who is a CYP2C19 Poor metabolizer with rs3781727 SNP wild or variant genotype Exclusion Criteria: - History of clinically significant respiratory, cardiovascular, renal, hepatic, hematologic, neurological disorder Healthy Volunteers null
Primary Outcomes
Measure: Pharmacokinetic outcome - Maximum plasma concentration (Cmax) Time: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-doseMeasure: Pharmacokinetic outcome - Area under the plasma concentration versus time curve (AUC) Time: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose